Cramer's pushed GILD all year, in lightning rounds on Mad Money saying it's a better pick than other biotech stocks people ask about, and in his other TheStreet.com outlets.
GILD is down less than 2% since the beginning of the calendar year, which is better than market average.
Market Data 
Markets 
AI
